Your browser doesn't support javascript.
loading
DNA base editing corrects common hemophilia A mutations and restores factor VIII expression in in vitro and ex vivo models.
Tonetto, Elena; Cucci, Alessia; Follenzi, Antonia; Bernardi, Francesco; Pinotti, Mirko; Balestra, Dario.
Afiliação
  • Tonetto E; Department of Life Sciences and Biotechnology and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), University of Ferrara, Ferrara, Italy.
  • Cucci A; Department of Health Sciences, School of Medicine, University of Piemonte Orientale, Novara, Italy.
  • Follenzi A; Department of Health Sciences, School of Medicine, University of Piemonte Orientale, Novara, Italy.
  • Bernardi F; Department of Life Sciences and Biotechnology and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), University of Ferrara, Ferrara, Italy.
  • Pinotti M; Department of Life Sciences and Biotechnology and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), University of Ferrara, Ferrara, Italy. Electronic address: pnm@unife.it.
  • Balestra D; Department of Life Sciences and Biotechnology and Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), University of Ferrara, Ferrara, Italy.
J Thromb Haemost ; 22(8): 2171-2183, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38718928
ABSTRACT

BACKGROUND:

Replacement and nonreplacement therapies effectively control bleeding in hemophilia A (HA) but imply lifelong interventions. Authorized gene addition therapy could provide a cure but still poses questions on durability. FVIIIgene correction would definitively restore factor (F)VIII production, as shown in animal models through nuclease-mediated homologous recombination (HR). However, low efficiency and potential off-target double-strand break still limit HR translatability.

OBJECTIVES:

To correct common model single point mutations leading to severe HA through the recently developed double-strand break/HR-independent base editing (BE) and prime editing (PE) approaches.

METHODS:

Screening for efficacy of BE/PE systems in HEK293T cells transiently expressing FVIII variants and validation at DNA (sequencing) and protein (enzyme-linked immunosorbent assay; activated partial thromboplastin time) level in stable clones. Evaluation of rescue in engineered blood outgrowth endothelial cells by lentiviral-mediated delivery of BE.

RESULTS:

Transient assays identified the best-performing BE/PE systems for each variant, with the highest rescue of FVIII expression (up to 25% of wild-type recombinant FVIII) for the p.R2166∗ and p.R2228Q mutations. In stable clones, we demonstrated that the mutation reversion on DNA (∼24%) was consistent with the rescue of FVIII secretion and activity of 20% to 30%. The lentiviral-mediated delivery of the selected BE systems was attempted in engineered blood outgrowth endothelial cells harboring the p.R2166∗ and p.R2228Q variants, which led to an appreciable and dose-dependent rescue of secreted functional FVIII.

CONCLUSION:

Overall data provide the first proof-of-concept for effective BE/PE-mediated correction of HA-causing mutations, which encourage studies in mouse models to develop a personalized cure for large cohorts of patients through a single intervention.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator VIII / Terapia Genética / Edição de Genes / Hemofilia A Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator VIII / Terapia Genética / Edição de Genes / Hemofilia A Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article